The clinical model behind every score.

OraPath operates an interpretive layer between the raw qPCR detection data and the clinical report. Raw bacterial DNA detection — useful in isolation — becomes substantively more useful when integrated through pattern-based classification, continuous burden scoring, and clinical decision support calibrated to the patient's specific microbial state. The interpretive layer is what turns molecular detection into clinical action.

OraPath's Pattern Identification algorithm classifies the core periodontal organism configuration against a verified pattern catalog. Fourteen patterns are documented in production — each tied to specific organism combinations and clinical evidence. The pattern catalog covers single-organism patterns (isolated Aa, isolated Fn-a), synergistic pairs (Pg + Td), expanded synergistic profiles, low-level early-detection patterns, and full-burden severity patterns.

Pattern matchers operate against organism detection above the noise floor, not just above clinical-relevance thresholds. Selected patterns:

• No Pathogens Detected (clean)— periodontal organisms below the noise floor
• Early Dysbiosis Pattern— a single low-level pathogen detected
• Isolated Aa Detection (aaIsolated)— Aa detected without core perio co-pathogens, treated conservatively per leukotoxin biology
• Pg + Td Synergistic Pattern (pgTd)— both detected above the noise floor, no additional core-perio organisms. Strong indicator of active periodontal disease
• High-Risk Synergistic Pattern (pgTdPlus)— Pg + Td plus Tf or Fa. Expanded red complex; advanced periodontal pattern. Score 5 by default; demoted to Score 4 by the moderate-only cap when no organism reaches the high-tier cutpoint
• Severe Multi-Pathogen Profile (fourPlus)— four or more core perio organisms detected; immediate professional evaluation indicated
• Additional patterns for amplifier-driven, bridge-driven, and dual-pathogen configurations

Each pattern carries clinical-reading text rendered directly on the report — calibrated for clinician reading without requiring methodology-page reference.

The Periodontal Risk Score is a 1–5 classification that integrates organism detection levels, pattern identification, and synergistic combinations into a band-labeled clinical reading. The five bands are Low Risk (1), Mild Risk (2), Moderate Risk (3), High Risk (4), and Severe Risk (5).

PRS is produced through the same algorithm whether the panel is Essentials, Comprehensive, PerioCaries, or Balance Test. The score operates on the six core periodontal organisms (Aa, Pg, Td, Tf, Fa, Fn-a) with organism-specific cutpoints and a documented set of scoring rules and caps. The moderate-only cap is the most operationally significant: a score of 5 is demoted to 4 when no organism reaches its high-tier cutpoint — preventing the most aggressive risk band from firing on configurations that don't include any individual high-tier detection.

Citation foundation:Socransky & Haffajee 1998, Hajishengallis 2015, Lamont 2018, Kilian 2016.

The Periodontal Pressure Score (0–100) is a continuous-burden complement to the 1–5 PRS. PPS quantifies the total weighted load across the six core perio organisms — surfacing treatment-response signals that the categorical PRS band cannot. A patient whose PRS holds steady at 4 across two visits can have a PPS that drops 20 points between visits, demonstrating measurable treatment response before the categorical risk score changes.

PPS is most clinically useful in treatment-response monitoring. The comparison page renders PPS deltas explicitly alongside the PRS band — making incremental improvement visible to both clinician and patient.

The Balance Test renders a four-score architecture that integrates the contributing forces in the microbiome into a single composite readout plus three named subscores.

The Oral Balance Score (0–100) is the headline integrated metric. Five bands: Severe Dysbiosis (0–24), High Imbalance (25–49), Imbalanced (50–69), Mild Shift (70–84), Well Balanced (85–100).

Three subscores break out the contributing dimensions:

• Protective Capacity Score— commensal abundance plus functional NO-producing resilience
• Disruptive Pressure Score— periodontal pathogen load plus caries-associated bacteria plus fungal overgrowth
• Nitric Oxide System Score— enterosalivary nitrate-nitrite-NO pathway capacity

PCS itself is a weighted composite of two named subscores: Commensal bacteria abundance, derived from the protective Streptococcus species, and Functional resilience, derived from the narG nitrate-reducing organisms. The subscore split makes the contributing layers of protective infrastructure legible.

A DPS-triggered severity ceiling applies a meta-penalty to the OBS when the Disruptive Pressure Score exceeds a defined threshold (rendered on the report as the "Severity ceiling: DPS ≥ [value]" flag), independent of which specific organisms drove the elevated DPS. The penalty surfaces explicitly on the rendered report with its point impact.

Citation foundation:Rosier 2018, Rosier 2020, Hezel & Weitzberg 2015, Marsh 2003.

The Balance Test measures four nitrate-reducing organisms (Rothia, Neisseria, Veillonella, Actinomyces) via their narG gene targets. These organisms convert dietary nitrate into nitrite, the upstream substrate for systemic nitric oxide production. The enterosalivary nitrate-nitrite-NO pathway supports circulation, immune balance, and tissue healing — and depleted NO-producing capacity is itself a clinical signal beyond what conventional pathogen-focused testing surfaces.

The Nitric Oxide System Score quantifies this capacity. The report renders the contributing organisms with their detection levels, the pathway diagram (dietary nitrate → salivary nitrate → oral bacteria conversion → systemic conversion → physiological benefits), and the clinical reading of the resulting score.

The Comprehensive Panel adds an Ecological Profile scoring layer operating on the bridging organisms (Pi, En, Cr, Pm, Pa), F. nucleatum total, early colonizers (Ec, Cs), and Candida. The Ecological Profile matches organism configurations against a verified catalog of ecological patterns; the Bridging Burden Score (0–100) quantifies the weighted load across the bridging organisms.

Selected ecological patterns:

• Quiescent Ecosystem— no clinically significant detections in the Comprehensive add-on panel
• Focal Orange-Complex Burden— one or two orange-complex organisms detected at high tier with a BBS in the Elevated band or above
• Polymicrobial Dysbiosis— four or more orange-complex organisms detected at meaningful levels alongside an Elevated BBS
• Active Inflammatory Bridging— multiple orange-complex bridging organisms at meaningful levels; reflects an active inflammatory ecosystem favoring transition from gingivitis to periodontitis
• Refractory Signal— Cr meaningful AND Pa meaningful; associated with treatment-resistant cases
• Necrotizing Signal— Td meaningful AND specific co-pathogen configuration; associated with necrotizing periodontal disease
• Pi-Dominant Pattern, Fungal Overgrowth, Early-Succession Pattern, and additional patterns for less common ecological configurations

The two-layer architecture — core periodontal scoring plus independent ecological scoring — is the substantive clinical-decision-support contribution of the Comprehensive Panel.

Citation foundation:Socransky & Haffajee 1998, Hajishengallis 2015, Marsh 2003.

Caries Risk is calculated for the Balance Test and PerioCaries Risk Report based on the detection levels of S. mutans and S. sobrinus. The risk classification uses the maximum DL of the two organisms against calibrated caries cutpoints, producing one of four labels: Minimal, Low, Moderate, or High.

Caries Risk operates as an independent clinical axis from the Periodontal Risk Score — the two can move separately, and the report renders them as twin primary signals on the PerioCaries Risk Report. The Balance Test renders Caries Risk as part of the integrated four-score picture.

Citation foundation:Takahashi & Nyvad 2011.

Every report renders a priority-ordered list of Clinical Focus Areas — calibrated recommendations drawn from a 13-item library. Each Focus Area carries a priority level (Critical, High, Moderate, Routine) and clinical-reading text specific to this patient's microbial state.

Focus Area selection is not generic. The algorithm operates on the specific PRS, PPS, pattern identification, Caries Risk, OBS subscore values, and ecological pattern present in this result. The algorithm doesn't just prioritize from a fixed list; it incorporates the patient's specific microbial state — including the OBS subscore values — as inputs to selection.

For example, the "Use targeted oral probiotic therapy" recommendation fires preferentially when Protective Capacity is high, on the clinical reasoning that probiotic intervention has more leverage when the protective infrastructure is intact and can amplify the introduced strains. The result is a recommendation set that reflects what's clinically actionable for this patient's specific microbial profile rather than generic guidance keyed to the risk classification.

The Antibiotic Considerations Report is a standalone rendering of the algorithmic prescribing decision support, generated on demand from any panel specimen. The same JSON dataset that produces the panel report can be rendered as an Antibiotic Considerations report through a popup dropdown at report-generation time — without re-running the laboratory test.

The algorithm operates in four steps:

• Indication check— does the clinical picture warrant antibiotic adjunct?
• Profile match— which regimen targets the specific organism configuration?
• Allergy filter— which regimens are excluded by reported allergies?
• Medical history filter— which regimens are contraindicated by reported medical history?

Four primary output paths: a recommended primary regimen with calibrated alternatives; a no-antibiotic-indicated determination with rationale; an allergy-filtered alternative regimen with excluded regimens enumerated for clinical transparency; and a medical-history-filtered alternative regimen.

Six regimens are calibrated in the catalog: Metronidazole + Amoxicillin (Pg-driven first-line), Doxycycline + Metronidazole (allergy alternative), Azithromycin, Clindamycin, Ciprofloxacin, and Doxycycline monotherapy. Each carries dosing, duration, clinical rationale, and the specific clinical context that selected it.

Citation foundation:Atieh et al. 2024, Walters & Lai 2015.

OraPath reports detection on a semi-quantitative log₂ Detection Level (DL) scale calibrated from the underlying qPCR Ct value:DL = max(0, 40 − Ct). Each +1 DL doubles the bacterial DNA quantity. The scale runs from DL 0 (approximately 1 copy) through DL 20 (approximately 1 million copies) with the practical clinical range falling between DL 3 (noise floor) and DL 20.

Per-organism cutpoints are calibrated to the clinical-relevance level for each organism — Aa at 4/8 (Moderate/High), most periodontal organisms at 10/14, caries organisms at 6/10, Candida at 6/12, protective organisms at 12/18. Cutpoints are documented in the methodology specifications and propagate consistently across every interpretive module.

Each report renders the DL scale with copy-number anchors, the per-organism cutpoint reference, and the noise-floor explanation — calibrated for the clinician reading the result, not just for laboratory specialists.

When a current specimen has a prior visit on record, the report includes a Treatment Response Comparison page rendering the change between visits. The comparison page surfaces three substantive clinical signals:

• Trajectory ribbon— Improving / Stable / Worsening / Substantially Worsening
• Pathogen-by-pathogen delta grid— DL changes per organism
• Clinical Focus Area Evolution block— which recommendations persist, which have resolved, and which are new

The comparison page is most clinically useful in cases where the categorical PRS band has not yet shifted but the underlying microbial picture has moved meaningfully. A patient whose PRS holds steady at 4 across two visits can have a PPS that has dropped 20+ points, multiple organisms cleared from detection, and a pattern transition from a more aggressive synergistic call to a less aggressive one — all visible on the comparison page even though the headline risk classification reads the same.

Every OraPath test is a Laboratory-Developed Test (LDT) under CLIA 42 U.S.C. § 263a. Validation parameters — analytical sensitivity, analytical specificity, accuracy, precision, reportable range, reference interval — are established and documented per IMMYLabs SOP prior to clinical release for every test on every panel.

Laboratory IMMYLabs, 133 Ed Noble Parkway, Norman, OK 73072 CLIA certification 37D2236199 COLA accreditation 32679 Laboratory Director Jeff McCormack, PhD, HCLD (ABB)

The HCLD/ABB credential — doctorate plus High Complexity Laboratory Director certification through the American Board of Bioanalysis — is the highest CLIA personnel qualification level for clinical laboratory directors performing high-complexity testing.

Tests have not been cleared or approved by the U.S. Food and Drug Administration; FDA clearance is not currently required for clinical LDT use. Results are adjunctive and must be interpreted by a qualified healthcare provider with clinical findings and history. Not intended to diagnose or treat disease.

This methodology page surfaces the substantive interpretive content. The complete algorithm specifications — including weighting coefficients, exact penalty rule structures, and validation data — are available through partnership conversation for qualified clinical evaluators, scientific reviewers, and academic partners.

Partnership conversation routes include scientific review for clinical-society endorsement, academic collaboration for research and publication, and specialty-domain partnerships for specialty report development (Cardiometabolic, Sports Performance, Reproductive Health & Pregnancy, Sleep & Airway, Pediatric Caries Risk, Cognitive & Neurological Health, Oncology Supportive Care).

Talk to our team about partnership

See the OraPath team